- Home
- BIIB vs PARAA Comparison
BIIB vs PARAA Comparison
Compare BIIB & PARAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PARAA
- Stock Information
- Founded
- BIIB 1978
- PARAA 1986
- Country
- BIIB United States
- PARAA United States
- Employees
- BIIB N/A
- PARAA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PARAA Broadcasting
- Sector
- BIIB Health Care
- PARAA Industrials
- Exchange
- BIIB Nasdaq
- PARAA Nasdaq
- Market Cap
- BIIB 18.8B
- PARAA 15.4B
- IPO Year
- BIIB 1991
- PARAA N/A
- Fundamental
- Price
- BIIB $127.50
- PARAA $23.27
- Analyst Decision
- BIIB Buy
- PARAA Hold
- Analyst Count
- BIIB 27
- PARAA 14
- Target Price
- BIIB $188.17
- PARAA $11.50
- AVG Volume (30 Days)
- BIIB 1.2M
- PARAA 30.6K
- Earning Date
- BIIB 07-31-2025
- PARAA 08-07-2025
- Dividend Yield
- BIIB N/A
- PARAA 0.87%
- EPS Growth
- BIIB 26.39
- PARAA N/A
- EPS
- BIIB 10.12
- PARAA N/A
- Revenue
- BIIB $9,816,400,000.00
- PARAA $28,720,000,000.00
- Revenue This Year
- BIIB N/A
- PARAA N/A
- Revenue Next Year
- BIIB N/A
- PARAA $0.67
- P/E Ratio
- BIIB $12.69
- PARAA N/A
- Revenue Growth
- BIIB 1.59
- PARAA N/A
- 52 Week Low
- BIIB $110.04
- PARAA $21.32
- 52 Week High
- BIIB $236.48
- PARAA $24.50
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- PARAA 60.65
- Support Level
- BIIB $132.37
- PARAA $22.80
- Resistance Level
- BIIB $137.84
- PARAA $23.09
- Average True Range (ATR)
- BIIB 4.12
- PARAA 0.31
- MACD
- BIIB 0.01
- PARAA 0.03
- Stochastic Oscillator
- BIIB 25.82
- PARAA 87.00
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PARAA Paramount Global
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.